Monte Rosa jumps on $150M license deal with Novartis
Monte Rosa will remain responsible for completion of the ongoing Phase 1 clinical study of MRT-6160 and is also eligible to ...
Business Insider28d
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
“Last year was transformative for Monte Rosa, with significant validation of our capabilities to design and develop ‘only-in-class’ MGDs for previously undruggable targets across a broad ...